July 31, 2020
|
August 5, 2020
|
August 29, 2023
|
March 22, 2021
|
May 31, 2025 (Final data collection date for primary outcome measure)
|
- Overall survival (OS) (Phase 3 only) [ Time Frame: 60 months ]
OS is defined as the time from randomization to death due to any cause
- Progression-free survival (PFS) per Response evaluation criteria in solid tumors (RECIST) version 1.1 according to investigator assessment (Phase 3 only) [ Time Frame: 36 months ]
PFS is defined as the time from randomization to the date of disease progression or death from any cause
- Incidence of dose-limiting toxicities (DLTs) (Phase 2 only) [ Time Frame: During first cycle of treatment; up to one month ]
- Incidence of adverse events (AEs) (Phase 2 only) [ Time Frame: 18 months ]
An adverse event is any untoward medical occurrence in a subject or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
- Incidence of laboratory abnormalities (Phase 2 only) [ Time Frame: 18 months ]
To be summarized using descriptive statistics.
- Incidence of dose modifications (Phase 2 only) [ Time Frame: 18 months ]
|
|
|
- Confirmed objective response rate (ORR) per RECIST version 1.1 according to investigator assessment (Phases 2 and 3) [ Time Frame: 36 months ]
ORR is defined as the proportion of subjects with best overall response of CR or PR
- ORR per RECIST version 1.1 according to investigator assessment (Phases 2 and 3) [ Time Frame: 36 months ]
ORR is defined as the proportion of subjects with best overall response of CR or PR
- Duration of response (DOR) per RECIST version 1.1 according to investigator assessment (Phases 2 and 3) [ Time Frame: 36 months ]
DOR is defined as the time from first documentation of objective response of CR or PR to the first documentation of disease progression or death from any cause
- Disease control rate (DCR) per RECIST version 1.1 according to investigator assessment (Phases 2 and 3) [ Time Frame: 36 months ]
DCR is defined as subjects with CR, PR, or stable disease (SD or non-CR/non-progressive disease)
- PFS per RECIST v1.1 according to blinded independent central review (BICR) assessment (Phase 3 only) [ Time Frame: 36 months ]
PFS is defined as the time from randomization to the date of disease progression or death from any cause
- Confirmed ORR per RECIST version 1.1 according to BICR assessment (Phase 3 only) [ Time Frame: 36 months ]
ORR is defined as the proportion of subjects with best overall response of CR or PR
- ORR per RECIST version 1.1 according to BICR assessment (Phase 3 only) [ Time Frame: 36 months ]
ORR is defined as the proportion of subjects with best overall response of CR or PR
- DOR per RECIST version 1.1 according to BICR assessment (Phase 3 only) [ Time Frame: 36 months ]
DOR is defined as the time from first documentation of objective response of CR or PR to the first documentation of disease progression or death from any cause
- DCR per RECIST version 1.1 according to BICR assessment (Phase 3 only) [ Time Frame: 36 months ]
DCR is defined as subjects with CR, PR, or stable disease (SD or non-CR/non-progressive disease)
- Incidence of AEs (Phase 3 only) [ Time Frame: 36 months ]
An adverse event is any untoward medical occurrence in a subject or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
- Incidence of laboratory abnormalities (Phase 3 only) [ Time Frame: 36 months ]
To be summarized using descriptive statistics.
- Incidence of dose modifications (Phase 3 only) [ Time Frame: 36 months ]
- PFS per RECIST version 1.1 according to investigator assessment (Phase 2 only) [ Time Frame: 18 months ]
PFS is defined as the time from the date of treatment initiation to the date of disease progression or death from any cause
- Area under the plasma concentration-time curve (AUC) to the time of the last quantifiable concentration (AUClast) of tucatinib (Phase 2 only) [ Time Frame: 1 month ]
Pharmacokinetic (PK) parameter
- AUC to AUClast of paclitaxel (Phase 2 only) [ Time Frame: 1 month ]
PK parameter
- Maximum observed concentration (Cmax) of tucatinib (Phase 2 only) [ Time Frame: 1 month ]
PK parameter
- Cmax of paclitaxel (Phase 2 only) [ Time Frame: 1 month ]
PK parameter
- Time of Cmax (Tmax) of tucatinib (Phase 2 only) [ Time Frame: 1 month ]
PK parameter
- Tmax of paclitaxel (Phase 2 only) [ Time Frame: 1 month ]
PK parameter
- Trough concentration (Ctrough) of tucatinib (Phase 2 only) [ Time Frame: 18 months ]
PK parameter
- Ctrough of paclitaxel (Phase 2 only) [ Time Frame: 18 months ]
PK parameter
- Metabolic ratio of tucatinib based on AUC (MRAUC) (Phase 2 only) [ Time Frame: 1 month ]
PK parameter
- MRAUC of paclitaxel (Phase 2 only) [ Time Frame: 1 month ]
PK parameter
- Time to deterioration of GEC symptoms as assessed by the European Organisation for Research and Treatment or Cancer (EORTC) quality of life questionnaire (QLQ)-C30 and EORTC QLQ-OG25 questionnaires. [ Time Frame: 36 months ]
The EORTC questionnaires measure aspects of health-related quality of life (HRQoL). Time to deterioration will be assessed in specific pre-specified single items from either the EORTC QLQ-C30 or EORTC QLQ OG25 and deterioration is defined as a 10-point increase from baseline in the symptom scales and a 10-point decrease from baseline for overall HRQoL.
- Change from baseline in health-related quality of life (HRQoL) [ Time Frame: 36 months ]
- Utility index values as assessed by the EQ-5D-5L [ Time Frame: 36 months ]
The EQ-5D-5L questionnaire is used as a preference based measurement of HRQoL outcomes. Data will be summarized using descriptive statistics.
|
- Confirmed objective response rate (ORR) per Response evaluation criteria in solid tumors (RECIST) version 1.1 according to investigator assessment (Phases 2 and 3) [ Time Frame: 36 months ]
Confirmed ORR is defined as confirmed complete response (CR) or partial response (PR) in subjects with measurable disease.
- ORR RECIST version 1.1 according to investigator assessment (Phases 2 and 3) [ Time Frame: 36 months ]
- Duration of response (DOR) per RECIST version 1.1 according to investigator assessment (Phases 2 and 3) [ Time Frame: 36 months ]
- Disease control rate (DCR) per RECIST version 1.1 according to investigator assessment (Phases 2 and 3) [ Time Frame: 36 months ]
DCR is defined as subjects with CR, PR, or stable disease (SD or non-CR/non-progressive disease)
- PFS per RECIST v1.1 according to blinded independent central review (BICR) assessment (Phase 3 only) [ Time Frame: 36 months ]
- Confirmed ORR per RECIST version 1.1 according to BICR assessment (Phase 3 only) [ Time Frame: 36 months ]
- ORR per RECIST version 1.1 according to BICR assessment (Phase 3 only) [ Time Frame: 36 months ]
- DOR per RECIST version 1.1 according to BICR assessment (Phase 3 only) [ Time Frame: 36 months ]
- DCR per RECIST version 1.1 according to BICR assessment (Phase 3 only) [ Time Frame: 36 months ]
- Incidence of AEs (Phase 3 only) [ Time Frame: 36 months ]
- Incidence of dose modifications (Phase 3 only) [ Time Frame: 36 months ]
- PFS per RECIST version 1.1 according to investigator assessment (Phase 2 only) [ Time Frame: 18 months ]
- Area under the plasma concentration-time curve (AUC) to the time of the last quantifiable concentration (AUClast) of tucatinib (Phase 2 only) [ Time Frame: 1 month ]
Pharmacokinetic (PK) parameter
- AUC to AUClast of paclitaxel (Phase 2 only) [ Time Frame: 1 month ]
PK parameter
- Maximum observed concentration (Cmax) of tucatinib (Phase 2 only) [ Time Frame: 1 month ]
PK parameter
- Cmax of paclitaxel (Phase 2 only) [ Time Frame: 1 month ]
PK parameter
- Time of Cmax (Tmax) of tucatinib (Phase 2 only) [ Time Frame: 1 month ]
PK parameter
- Tmax of paclitaxel (Phase 2 only) [ Time Frame: 1 month ]
PK parameter
- Trough concentration (Ctrough) of tucatinib (Phase 2 only) [ Time Frame: 18 months ]
PK parameter
- Ctrough of tucatinib (Phase 2 only) [ Time Frame: 18 months ]
PK parameter
- Metabolic ratio of tucatinib based on AUC (MRAUC) (Phase 2 only) [ Time Frame: 1 month ]
PK parameter
- MRAUC of paclitaxel (Phase 2 only) [ Time Frame: 1 month ]
PK parameter
|
Not Provided
|
Not Provided
|
|
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
|
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
|
This study is being done to see if tucatinib with trastuzumab, ramucirumab and paclitaxel works better than ramucirumab and paclitaxel to treat HER2-positive (HER2+) cancer of the gut (stomach or gastroesophageal cancer). This study will also look at what side effects happen when participants take this combination of drugs. A side effect is anything the drug does other than treating cancer.
Study treatment will be given in 28-day cycles.
In the Phase 2 part of the trial, participants and their doctors will know what drugs are being given (open-label). In the Phase 3 part, the study is "blinded." This means that participants, their doctor, and the study sponsor will not know which drugs are being given.
|
Not Provided
|
Interventional
|
Phase 2 Phase 3
|
Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment
|
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Adenocarcinoma
|
- Drug: tucatinib
300 mg given twice daily orally
Other Name: TUKYSA, ONT-380, ARRY-380
- Drug: trastuzumab
6 mg/kg loading dose will be administered intravenously (IV; into the vein) on Cycle 1 Day 1, followed by 4 mg/kg IV on Cycle 1 Day 15 and then Days 1 and 15 of each cycle thereafter
- Drug: ramucirumab
8 mg/kg will be administered IV on Days 1 and 15 of each cycle
Other Name: CYRAMZA
- Drug: paclitaxel
60 or 80 mg/m^2 IV on Days 1, 8, and 15 of each cycle
- Other: tucatinib placebo
Given twice daily orally
- Other: trastuzumab placebo
IV on Days 1 and 15 of each cycle
|
- Experimental: Phase 2 Arm
Tucatinib + trastuzumab + ramucirumab + paclitaxel
Interventions:
- Drug: tucatinib
- Drug: trastuzumab
- Drug: ramucirumab
- Drug: paclitaxel
- Experimental: Arm 3A
Tucatinib + trastuzumab + ramucirumab + paclitaxel
Interventions:
- Drug: tucatinib
- Drug: trastuzumab
- Drug: ramucirumab
- Drug: paclitaxel
- Active Comparator: Arm 3B
Ramucirumab + paclitaxel + tucatinib placebo + trastuzumab placebo
Interventions:
- Drug: ramucirumab
- Drug: paclitaxel
- Other: tucatinib placebo
- Other: trastuzumab placebo
- Experimental: Arm 3C
Tucatinib + ramucirumab + paclitaxel + trastuzumab placebo
Interventions:
- Drug: tucatinib
- Drug: ramucirumab
- Drug: paclitaxel
- Other: trastuzumab placebo
|
Not Provided
|
|
Active, not recruiting
|
17
|
566
|
March 31, 2027
|
May 31, 2025 (Final data collection date for primary outcome measure)
|
Inclusion Criteria:
Exclusion Criteria:
- Subjects with squamous cell or undifferentiated GEC
- Having received more than 1 line of prior systemic therapy for locally-advanced unresectable or metastatic disease
- Having received taxanes ≤12 months prior to enrollment, prior treatment with ramucirumab, or prior treatment with tucatinib, lapatinib, neratinib, afatinib, or any other investigational anti-HER2 and/or anti-EGFR tyrosine kinase inhibitor, or with T-DM1, T-Dxd, or any other HER2-directed antibody-drug conjugate
- Phase 2 paclitaxel dose optimization stage only: history of prior partial or total gastrectomy
- Unable to swallow pills
|
Sexes Eligible for Study: |
All |
|
18 Years and older (Adult, Older Adult)
|
No
|
Contact information is only displayed when the study is recruiting subjects
|
Australia, Canada, Korea, Republic of, Taiwan, United Kingdom, United States
|
|
|
NCT04499924
|
SGNTUC-022
|
Yes
|
Studies a U.S. FDA-regulated Drug Product: |
Yes |
Studies a U.S. FDA-regulated Device Product: |
No |
|
Not Provided
|
Seagen Inc.
|
Same as current
|
Seagen Inc.
|
Same as current
|
Not Provided
|
Study Director: |
JoAl Mayor, PharmD, BCOP |
Seagen Inc. |
Study Director: |
Michelle Ubowski, PharmD |
Seagen Inc. |
|
Seagen Inc.
|
August 2023
|